Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L) Financial Performance & Income Statement Overview
Review Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Eckert & Ziegler Strahlen- und Medizintechnik AG 0NZY.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $68.19M | $80.36M | $70.10M | $77.80M |
| Cost of Revenue | $34.11M | $44.12M | $36.09M | $39.67M |
| Gross Profit | $34.08M | $36.23M | $34.005M | $38.13M |
| Gross Profit Ratio | $0.50 | $0.45 | $0.49 | $0.49 |
| R&D Expenses | $0.00 | $4.86M | $0.00 | $0.00 |
| SG&A Expenses | $17.53M | $19.51M | $16.40M | $19.05M |
| Operating Expenses | $18.31M | $21.86M | $18.38M | $21.14M |
| Total Costs & Expenses | $52.43M | $65.98M | $54.60M | $60.30M |
| Interest Income | $715000.00 | $748000.00 | $534000.00 | $517000.00 |
| Interest Expense | $725000.00 | $784000.00 | $925000.00 | $1.09M |
| Depreciation & Amortization | $3.21M | $8.71M | $3.58M | $3.36M |
| EBITDA | $18.88M | $24.38M | $18.34M | $20.51M |
| EBITDA Ratio | $0.28 | $0.30 | $0.26 | $0.26 |
| Operating Income | $15.77M | $14.38M | $15.50M | $16.95M |
| Operating Income Ratio | $0.23 | $0.18 | $0.22 | $0.22 |
| Other Income/Expenses (Net) | -$829000.00 | $504000.00 | -$1.56M | -$886000.00 |
| Income Before Tax | $14.94M | $14.88M | $13.84M | $15.81M |
| Income Before Tax Ratio | $0.22 | $0.19 | $0.20 | $0.20 |
| Income Tax Expense | $5.11M | $3.91M | $4.42M | -$9.50M |
| Net Income | $9.69M | $9.90M | $5.30M | $9.54M |
| Net Income Ratio | $0.14 | $0.12 | $0.08 | $0.12 |
| EPS | $0.46 | $0.48 | $0.26 | $0.46 |
| Diluted EPS | $0.46 | $0.48 | $0.26 | $0.46 |
| Weighted Avg Shares Outstanding | $20.85M | $20.84M | $20.84M | $20.84M |
| Weighted Avg Shares Outstanding (Diluted) | $20.91M | $20.85M | $20.85M | $20.84M |
Financial performance has remained strong, with revenue growing from $77.80M in Q2 2024 to $68.19M in Q1 2025. Gross profit continued to perform well, with margins at 50% in the latest quarter. Operating income reached $15.77M in Q1 2025, holding a steady 23% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $18.88M. Net income dropped to $9.69M, keeping EPS at $0.46. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan